Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2652MR)

This product GTTS-WQ2652MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Non-small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2652MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9337MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ9249MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ10700MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ12620MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ12038MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ6483MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ14861MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ6352MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW